AI tumor board review for GU cancers
Delibera gives the physician treating GU cancer (prostate to start, bladder and kidney next) a written review from every specialty on the board: every position in its own words, where they disagree, the evidence behind them, and what the record still needs.
Each position is written by an AI model configured to one specialty, so the treating physician sees how every discipline weighs the case.
By cancer
How a GU tumor board weighs each cancer
- Prostate cancerAvailable now
- Recurrence after prostatectomy, PSMA PET findings, and how much metastatic disease changes systemic therapy.
- Bladder cancerIn development
- Bladder preservation or cystectomy, neoadjuvant chemotherapy, and BCG-unresponsive non-muscle-invasive disease.
- Kidney cancerIn development
- Small renal masses, adjuvant therapy after nephrectomy, and first-line therapy for metastatic disease.
Who sits at the board
Who sits at a GU tumor board
- Urology
- Surgery, from prostatectomy and cystectomy to partial or radical nephrectomy, and the endoscopic and intravesical care of early bladder cancer.
- Medical oncology
- Systemic therapy, from hormone therapy in prostate cancer to chemotherapy and immunotherapy in bladder and kidney cancer.
- Radiation oncology
- Curative and salvage radiation, chemoradiation that keeps the bladder, and targeted radiation to limited metastases.
- Pathology
- Grade, stage and histology from the biopsy or the surgical specimen: the facts most other positions rest on.
- Radiology and nuclear medicine
- What the imaging shows and how certain it is, including PSMA PET in prostate cancer.
What the review contains
One written review for each patient
- The case as the records state it, with every gap marked and none filled in.
- Each specialty’s position in its own words, and where it disagreed with another.
- What the record still needs, and what to do under each possible answer.
- Every source the board drew on, marked by how it was used, with a link to each.
Who it is for
For community urology and oncology
- Urologists and oncologists in community practice
- Every discipline’s reasoning on a GU case, in writing, before the plan is set.
- Practices that refer to academic cancer centers
- The review can travel with the referral, so the receiving team starts from every discipline’s position and the questions still open.
Request access for your practice
Prostate cancer reviews are available now; bladder and kidney cancer reviews are in development. We read every request and will get back to you within two business days.
Request access